The effect of a continuous regimen of drospirenone 3mg/ethinylestradiol 30μgon Cox-2 and Ki-67 expression in the endometrium

European Journal of Contraception and Reproductive Health Care

Volumn 15, Issue 1, 2010, Pages 35-40

  Maia Jr , Hugo ^a   Casoy, Julio ^a   Athayde, Clia ^a   Valente Filho, Jorge ^a   Coutinho, Elsimar M ^a  

^a Centro De Pesquisa E Assistencia Em Reproducao Humana   (Brazil)

Author keywords

Breakthrough bleeding; Cox 2; Drospirenone; Dysmenorrhoea; Endometrium; Extended regimen

Indexed keywords

CYCLOOXYGENASE 2; DROSPIRENONE PLUS ETHINYLESTRADIOL; KI 67 ANTIGEN;

ADULT; AMENORRHEA; ARTICLE; BREAKTHROUGH BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DYSMENORRHEA; ENDOMETRIUM; ENDOMETRIUM ABLATION; FEMALE; HUMAN; HUMAN TISSUE; HYSTEROSCOPY; IMMUNOHISTOCHEMISTRY; MENORRHAGIA; MENSTRUAL CYCLE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE BLEEDING PATTERN;

ADULT; ALDOSTERONE ANTAGONISTS; ANDROSTENES; CONTRACEPTIVES, ORAL, SYNTHETIC; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIUM; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HUMANS; KI-67 ANTIGEN; OBSERVATION; UTERINE HEMORRHAGE;

EID: 77249164177     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625180903383928     Document Type: Article

References (19)

1. Archer DF. Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives. Contraception 2006;74:359-366
2. Edelman A, Gallo MF, Nichols MD, et al. Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials. Hum Reprod 2006;21:573-578
3. Vandever MA, Kuehl TJ, Sulak PJ, et al. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens. Contraception 2008;77:162-170
4. Maia H Jr, Casoy J, Pimentel K, et al. Effect of oral contraceptives on vascular endothelial growth factor, Cox-2 and aromatase expression in the endometrium of uteri affected by myomas and associated pathologies. Contraception 2008;78:479-485
5. Maia HJ, Casoy J. Non-contraceptive health benefits of oral contraceptives. Eur J Contracept Reprod Health Care 2008;13:17-24.
6. Sugino N, Karube-Harada A, Taketani T, et al. Withdrawal of ovarian steroids stimulates prostaglandin F2a production through nuclear factor-kB activation via oxygen radicals in human endometrial stromal cells: potential relevance to menstruation. J Reprod Dev 2004; 50:215-225
7. Smith OP, Jabbour HN, Critchley HO. Cyclooxygenase enzyme expression and E series prostaglandin receptor signalling are enhanced in heavy menstruation. Hum Reprod 2007;22:1450-1456
8. Maia H, Correia T, Freitas L, et al. Cyclooxygenase-2 expression in the endometrium and its relationship to bleeding in users of continuous oral contraceptives. Gynecol Endocrinol 2006;22:96-100.
9. Rhoton-Vlasak A, Chegini N, Hardt N, Williams RS. Histological characteristics and altered expression of interleukins (IL) IL-13 and IL-15 in endometria of levonorgestrel users with different uterine bleeding patterns. Fertil Steril 2005;83:659-665
10. Coffee AL, Sulak PJ, Kuehl TJ. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 2007;75: 444-449
11. Grow DR, Iromloo K. Oral contraceptives maintain a very thin endometrium before operative hysteroscopy. Fertil Steril 2006;85:204-207
12. Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261-266
13. Lau TM, Witjaksono J, Affandi B, Roqers PA. Expression of progesterone receptor mRNA in the endometrium during the normal menstrual cycle and in Norplant users. Hum Reprod 1996;11:2629-2634
14. Critchley HO, Jones RL, Lea RG, et al. Role of inflammatory mediators in human endometrium during progesterone withdrawal and early pregnancy. J Clin Endocrinol Metab 1999;84:240-248
15. Nathirojanakun P, Taneepanichskul S, Sappakitkumjorn N. Efficacy of a selective COX-2 inhibitor for controlling irregular uterine bleeding in DMPA users. Contraception 2006;73:584-587
16. Hayes EC, Rock JA. COX-2 inhibitors and their role in gynecology. Obstet Gynecol Surv 2002;57:768-780
17. Kastner P, Krust A, Turcotte B, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO Journal 1990;9: 1603-1614
18. Foidart JM, Sulak PJ, Schellschmidt I, Zimmermann D; Yasmin Extended Regimen Study Group. The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days. Contraception 2006;73:34-40.
19. Sales KJ, Jabbour HN. Cyclooxygenase enzymes and prostaglandins in pathology of the endometrium. Reproduction 2003;126:559-567